Biological Soft X-ray Tomography at the Advanced Light Source

先进光源下的生物软 X 射线断层扫描

基本信息

项目摘要

Project Summary/Abstract The National Center for X-ray Tomography (NCXT) is a full-service, user facility for biomedical imaging and research. NCXT Users, whether working on site or remotely, have access to specialized microscopes and imaging techniques, in particular soft x-ray tomography (SXT) and super-resolution cryogenic fluorescence tomography (SR-CFT). In the US, these imaging modalities are only available at the NCXT. SXT microscopes visualize and quantify the mesoscale organization of biological cells, including large eukaryotic cells. No stains or contrast agents are required for SXT imaging. Before being imaged by the NCXT's transmission soft x-ray microscope at the Advanced Light Source, cells are rapidly cryo-preserved; the only pre-imaging step required. SXT is highly complementary to other imaging modalities, particularly fluorescence and electron microscopies. Mesoscale, 3D SXT reconstructions of an entire cell act as a framework for the interpretation of other types of imaging and biophysical data, allowing them to be viewed in the context of the whole cell. XM2 is currently the only microscope of its kind in the Nation. The requested P30 funding will support the day-to-day operation of XM-2, together with the associated user program and specimen preparation laboratories, and a program of upgrades to our software/computing resources. During the funding cycle, we will achieve the following specific aims: Aim 1: Give the biomedical research community access to soft x-ray tomography (SXT). The work of this aim ensures imaging cells by SXT remains an option open to US researchers. Significant consideration will be given to making the Resource as user-friendly as possible, particular towards the community of researchers that work remotely. Aim 2: Maintain and calibrate XM-2, the NCXT operated soft x-ray microscope at the ALS. As with all synchrotron beamlines, XM-2 is a sophisticated instrument that requires regular maintenance and calibration. We will take a programmatic approach to ensure XM-2 is robust, reliable, and operates with minimum unscheduled downtime. Aim 3: Implement upgrades and enhancements to ensure the NCXT remains `state-of-the-art.' Over the timescale of the funding cycle, new hardware, software, and algorithms will become available, and some existing components will reach their end-of-life. We will, therefore, carry out upgrades and enhancements to maintain the NCXT at the `state-of-the-art.'
项目概要/摘要 国家 X 射线断层扫描中心 (NCXT) 是一个提供全方位服务的用户设施 生物医学成像和研究。 NCXT 用户,无论是现场工作还是远程工作, 能够使用专门的显微镜和成像技术,特别是软 X 射线 断层扫描 (SXT) 和超分辨率低温荧光 断层扫描(SR-CFT)。在美国,这些成像方式仅在 NCXT。 SXT 显微镜可视化并量化生物细胞的介观组织, 包括大型真核细胞。 SXT 不需要染色剂或造影剂 成像。在由 NCXT 的透射软 X 射线显微镜成像之前 先进光源,细胞快速冷冻保存;唯一的预成像步骤 必需的。 SXT 与其他成像方式高度互补,特别是荧光和 电子显微镜。整个细胞的中尺度 3D SXT 重建充当 解释其他类型的成像和生物物理数据的框架, 允许在整个细胞的背景下查看它们。 XM2 是目前国内唯一的同类显微镜。要求的P30 资金将支持 XM-2 以及相关的日常运营 用户计划和样本制备实验室,以及我们的升级计划 软件/计算资源。在融资周期内,我们将实现以下目标 具体目标: 目标 1:为生物医学研究界提供软 X 射线 断层扫描(SXT)。这一目标的工作确保 SXT 成像细胞仍然是 选项向美国研究人员开放。将认真考虑使 资源尽可能方便用户,特别是对研究人员社区 远程工作。 目标 2:维护和校准 XM-2,NCXT 操作的软 X 射线 ALS 的显微镜。与所有同步加速器光束线一样,XM-2 是一种先进的 需要定期维护和校准的仪器。我们将采取一个 编程方法确保 XM-2 稳健、可靠,并以最少的成本运行 计划外停机。 目标 3:实施升级和增强以确保 NCXT 仍然是“最先进的”。在融资周期的时间范围内,新硬件、 软件和算法将变得可用,并且一些现有组件将变得可用 到达生命的终点。因此,我们将进行升级和增强 使 NCXT 保持“最先进”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carolyn A Larabell其他文献

Carolyn A Larabell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carolyn A Larabell', 18)}}的其他基金

User Training and Outreach
用户培训和推广
  • 批准号:
    10037806
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Administration
行政
  • 批准号:
    10491214
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Technology Operations Core
技术运营核心
  • 批准号:
    10491223
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Administration
行政
  • 批准号:
    10710225
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Biological Soft X-ray Tomography at the Advanced Light Source
先进光源下的生物软 X 射线断层扫描
  • 批准号:
    10710224
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Administration
行政
  • 批准号:
    10037805
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Biological Soft X-ray Tomography at the Advanced Light Source
先进光源下的生物软 X 射线断层扫描
  • 批准号:
    10037804
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
User Training and Outreach
用户培训和推广
  • 批准号:
    10282435
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Technology Operations Core
技术运营核心
  • 批准号:
    10282436
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:
Biological Soft X-ray Tomography at the Advanced Light Source
先进光源下的生物软 X 射线断层扫描
  • 批准号:
    10282433
  • 财政年份:
    2020
  • 资助金额:
    $ 88.57万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 88.57万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了